SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trilogy Metals, Inc. engages in the development and exploration of mineral properties. The firm holds interests in the Upper Kobuk mineral projects that include the Arctic, a copper-zinc-lead-gold-silver and Bornite, a carbonate-hosted copper projects, which is located in the Ambler mining district in Northwest Alaska. The company was founded on April 27, 2011 and is headquartered in Vancouver, Canada.

Trilogy Metals Inc

Trilogy Metals is trending due to a recent government investment, sparking significant community discussion around the company's potential and the strategic importance of domestic mineral sourcing. Community members are actively discussing options trading, potential short squeezes, and the possibility of further gains, while also noting the company's connection to critical minerals and government initiatives. The stock's surge has triggered both excitement and caution, with some highlighting the potential for volatility.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ is trending following news of a collaboration to enhance cybersecurity for North America's energy infrastructure, with community members highlighting its potential in the quantum security space. Discussions revolve around the stock's potential to reach double digits, with some suggesting it is undervalued compared to its peers. Some investors believe $LAES is primed for significant growth due to its positioning in the burgeoning quantum computing and AI sectors.

American Resources Corp. engages in the extraction, processing, transportation, and distribution of metallurgical coal to the steel industry. It focuses on the operation of coal mining complexes located primarily within Pike, Knott, and Letcher Counties, Kentucky, and Wyoming County, West Virginia. The company was founded in 2006 and in headquartered in Fishers, IN.

American Resources Corporation - Ordinary Shares - Class A

American Resources Corporation ($AREC) is trending due to recent retail interest and news of a $33 million equity deal to fund rare earth initiatives. Community members are discussing the company's potential in the rare earth and critical minerals sector, drawing comparisons to other soaring stocks in the industry. Some investors are speculating about a potential ReElement IPO and the impact of government backing on the company.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors discuss a potential short squeeze and the company's strategic shift toward AI data centers, particularly following a significant note offering to fund expansion. Community members are actively debating price targets, technical resistance levels, and the impact of high short interest. Bullish sentiment is fueled by the Google-backed AI data center deal and anticipation of future contracts.

Greenwave Technology Solutions, Inc. is an emerging growth company, which engages in recycling ferrous metal. It also recycles nonferrous metals including aluminum, copper, stainless steel, nickel, brass, titanium, lead, alloys, and mixed metal products. The company was founded on April 26, 2013 and is headquartered in Chesapeake, VA.

Greenwave Technology Solutions Inc

GWAV is experiencing significant volatility, driving interest in the stock. The community is actively debating a potential short squeeze amid a low float, while others express concern regarding the company's fundamentals and past dilution. Revenue growth and government funding related to rare earth metals are also being mentioned as potential catalysts.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors discuss the possibility of a company sale following a letter from a major shareholder, Shah Capital, expressing dissatisfaction with COVID vaccine sales. The community speculates on potential buyout offers from Sanofi or Merck, with some aiming for a price of $25 or higher per share. Discussions also involve the potential of Novavax's Matrix-M adjuvant and the need for a CEO with a clear plan.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending amid community discussion regarding a recent term loan facility; while some express disappointment over the lack of a partnership and concerns about the loan's interest rate given the company's revenue status, others view it as a positive sign of confidence in the company's prospects and a better alternative to dilution. The community is also focused on upcoming data releases and potential catalysts, including a possible buyout.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Federal National Mortgage Association ($FNMA) is trending as investors debate the potential impacts of a government shutdown, recent housing finance discussions, and speculation around an upcoming IPO. Community members are actively discussing potential share dilution, institutional investment, and the influence of key figures like Bill Pulte and government officials. Some traders express concern about market manipulation and volatility, while others remain optimistic about long-term gains.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending following the release of its Q3 earnings report, with discussion centering on the bank's performance relative to expectations and broader economic implications. Community members are weighing in on whether the initial market reaction represents a buying opportunity or a signal of underlying weakness, particularly in light of CEO Jamie Dimon's cautious outlook.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending due to news of supporting NVIDIA's next-generation AI factory computing platforms, sparking excitement around its role in AI infrastructure. The community is discussing potential short squeezes and long-term growth, while also weighing caution after a significant price jump. Some believe NVTS could be the next big player in the AI-driven semiconductor sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Pasithea Therapeutics garnered heightened retail buzz on Tuesday after the firm announced preclinical results showing that its experimental drug, PAS-004, effectively blocked ETS2 signaling, which controls inflammation in IBD and other immune conditions.Research from the Francis Crick Institute found PAS-004 more effective than selumetinib at reducing the expression of ETS2-regulated genes and macrophage functions essential for cytokine production and phagocytosis.Pasithea Therapeutics shares ended Tuesday at $0.98, with a 3.77% gain, but they fell back 4.17% to $0.94 during after-hours trading.According to Lee, who published a 2024 Nature paper identifying ETS2 as an essential regulator of IBD-related inflammation, the findings suggest PAS-004 could provide broader inhibition of inflammatory pathways compared to selumetinib and therapies that target individual cytokines or rely on JAK inhibition.According to Pasithea CEO Tiago Reis Marques, data findings show PAS-004's potential for treating chronic inflammatory diseases and its existing cancer application.&nbsp;Safety data from Phase 1 trials in advanced cancer patients suggest that the drug appears to show good tolerance in wider therapeutic uses.The firm announced its plan to move PAS-004 into proof-of-concept research targeting inflammatory disorders, including IBD and ankylosing spondylitis.On Stocktwits, retail sentiment was ‘bullish’ amid a 7,450% surge in 24-hour message volume.One user&nbsp;was “infuriated” after exiting a position in Pasithea Therapeutics (KTTA) at a loss after buying in at $1.18 and selling at $0.92, only to see the stock rise afterward.<stembedurl>https://stocktwits.com/Cdeezhands/message/615259857</stembedurl>Another user noted that Pasithea’s recent news was encouraging and pointed to the stock’s price movement from around $2.08 in April to $2.48 in early May as a sign of potential for organic upside.<stembedurl>https://stocktwits.com/stocktrade77/message/615239372</stembedurl>The stock has declined 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Pasithea Therapeutics Stock Draws Retail Buzz As Early Data Shows Potential In Treating Inflammatory Diseases

The company saw increased retail chatter after new preclinical data showed its drug, PAS-004, effectively blocks inflammation pathways linked to IBD and other immune diseases. 

Equity

The company saw increased retail chatter after new preclinical data showed its drug, PAS-004, effectively blocks inflammation pathways linked to IBD and other immune diseases. The company plans to advance PAS-004 into further studies targeting inflammatory conditions.

Shares of Theriva Biologics fell sharply after the company priced a public offering of up to 6.8 million shares of common stock and accompanying warrants at $1.10 per unit.&nbsp;The offering is expected to raise nearly $7.5 million in gross proceeds, before deducting placement agent fees and other offering expenses.&nbsp;The warrants will be exercisable immediately at the same price of $1.10 per share and will expire in five years.Theriva shares closed at $0.81, down 41% on Wednesday. After hours, shares dropped to $0.75, reflecting a further 7.4% decline.The offering follows the announcement of positive topline results from the Virage Phase 2b clinical trial, which evaluated VCN-01 in combination with standard chemotherapy for treating metastatic pancreatic ductal adenocarcinoma (PDAC).&nbsp;The study, which included 96 newly diagnosed metastatic PDAC patients, showed that patients receiving VCN-01 plus chemotherapy had a median overall survival (OS) of 10.8 months, compared to 8.6 months in the control group receiving chemotherapy alone.&nbsp;Additionally, the VCN-01+chemotherapy arm showed a median duration of response (DoR) of 11.2 months, double that of the control arm’s 5.4 months.Theriva intends to use the proceeds primarily for working capital, general corporate purposes, and research and development.&nbsp;A portion of the funds may also be used for manufacturing scale-up or potential acquisitions, although no specific deals are currently in place.&nbsp;A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.On Stocktwits, sentiment was described as ‘extremely bullish’, with ‘high’ message volume fueling speculation about the company’s future.&nbsp;One user speculated that a buyout could still be in play, potentially happening before September 30. This user noted that while the offering would dilute the stock, buying at current levels could offer significant upside in the event of a buyout.<stembedurl>https://stocktwits.com/exwallstcfo/message/613861348</stembedurl>Another user drew comparisons between Theriva and Pasithea Therapeutics, suggesting that both companies had positive news followed by public offerings.&nbsp;The user speculated that the offering could have been strategically timed to benefit from a price pump.<stembedurl>https://stocktwits.com/Staceykyusa/message/613855430</stembedurl>Shares of Theriva have fallen nearly 51% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a chart depicting stock market crash, is displayed on a mobile phone screen in Ankara, Turkiye on August 5, 2024. (Photo by Osmancan Gurdogan/Anadolu via Getty Images)

Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01.

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01, in combination with standard chemotherapy. 

Shares of Pasithea Therapeutics Corp. (KTTA) soared as high as about 150% on Tuesday morning before paring back most of the gains after it announced positive data from its ongoing Phase 1 trial of PAS-004 in advanced cancer patients.PAS-004 is a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) and other mitogen-activated protein kinase (MAPK) pathway driven cancer indications.The clinical-stage biotechnology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/06/3074902/0/en/Pasithea-Therapeutics-Reports-Positive-Pharmacodynamic-Results-Demonstrating-Robust-Target-Engagement-from-its-Ongoing-Phase-1-Clinical-Trial-of-PAS-004.html">said</a> that several patients achieved stable disease and tumor shrinkage while on the treatment.A patient being treated with 15-milligram capsules of PAS-004 with stage 4 pancreatic cancer achieved a tumor volume reduction of 9.8% over 5 months of PAS-004 treatment, the company said. The patients currently remain in the study, it added.Certain biomarkers also confirmed the capsule’s MEK inhibitor activity and substantial target engagement, the company said.The Phase 1 trial is aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004 in patients with MAPK pathway-driven advanced solid tumors.The recently announced data include results from patients treated with 8mg, 15mg, and 4mg tablets of PAS-004.In April, the company also dosed three subjects with 30mg capsules of PAS-004.The company then said it expects to complete enrollment of all patients in the trial by the end of 2025.On Stocktwits, retail sentiment around Pasithea jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:633/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_06_at_10_44_26_AM_png_4ec77b8998.webp" alt="KTTA's Sentiment Meter and Message Volume as of 10:45 a.m. ET on May 6, 2025 | Source: Stocktwits" width="633" height="62"><figcaption>KTTA's Sentiment Meter and Message Volume as of 10:45 a.m. ET on May 6, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/KTTA">KTTA stock</a> is down by about 42% this year and by about 76% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/economist-kenneth-rogoff-believes-trump-trade-policy-is-speeding-up-dollar-decline/chiIJtJRbS7">Economist Kenneth Rogoff Believes Trump’s Trade Policy Is Speeding Up Dollar’s Decline, Calls Navarro President’s ‘Rasputin’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated

The clinical-stage biotechnology company said several patients achieved stable disease and tumor shrinkage while on the treatment.

Shares of Pasithea Therapeutics Corp. (KTTA) surged nearly 47% on Thursday, closing at a two-month high, after an external committee approved advancing its cancer drug trial to the next dosing cohort.The news also resulted in the company's stock drawing the highest jump in retail investor chatter among healthcare stocks on Stocktwits.&nbsp;Message volume about KTTA soared by a whopping 48,000% by late Thursday, while sentiment flipped to 'extremely bullish' from 'bearish' a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/KTTA_sentiment_and_message_volume_April_10_png_57f0ce9213.webp" alt="KTTA sentiment and message volume April 10.png" width="1318" height="316"><figcaption>KTTA sentiment and message volume April 10. | source: Stocktwits</figcaption></figure>Pasithea said that its Phase 1 clinical trial of PAS-004 for advanced cancer has been cleared to advance to Cohort 6 (30mg capsule), following a recommendation from the independent Safety Review Committee.&nbsp;The decision was based on safety data from three patients in Cohort 5, with no dose-limiting toxicities (DLTs) reported.Notably, none of the first 19 patients — across both capsule and tablet formulations — have experienced rash, a common and often dose-limiting side effect seen with competitor MEK inhibitors.The ongoing trial is a multi-center, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004.&nbsp;One bullish watcher said the stock "will probably open at $2.18" on Friday, implying a more than 35% jump from the last close.<stembedurl>https://stocktwits.com/Nifty_Trader/message/611306648</stembedurl>Another user recommended holding the stock for a week or two and it "should be at $5 or $7."<stembedurl>https://stocktwits.com/MommoTrader/message/611306390</stembedurl><a href="https://stocktwits.com/symbol/KTTA">Pasithea stock</a> has lost nearly 50% this year. Shares were up marginally in Thursday's after-hours trading.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort

The decision was based on safety data from three patients in Cohort 5, with no dose-limiting toxicities reported.

11 Undervalued Stocks for Less Than $50 in April 2024

These inexpensive and undervalued stocks are top performers with strong upside potential based on their price-to-book ratio

 Steve Russell / Contributor

Neuroscience-focused biotechnology firm...

Pasithea Therapeutics Corp trading halted, volatility trading pause

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern...

Pasithea Therapeutics announces invention of crystalline form of PAS-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

-- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio -- SOUTH SAN FRANCISCO...

Pasithea Therapeutics announces FDA acceptance of IND application for PAS-004

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Lawrence J. Steinman on May 12, 2020 and is headquartered in Miami Beach, FL.

Pasithea Therapeutics Corp

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

KTTA
Pasithea Therapeutics Corp

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest KTTA News

KTTAPasithea Therapeutics Corp